TET2 and neoplasm: Consistently, antibody-based depletion of CD4+ and CD8+ T-cells (by intraperitoneal injection of an anti-CD8 mAb, 53-6.72 clone, and an anti-CD4 mAb, GK1.5 clone, 400 μg each, every 7 days from day 7 after cancer cells injection) rescued the reduced tumor growth phenotype in Mye-Tet2 null mice, thus overcoming the blockade of the immunosuppressive activity of TAMs [104].